(HealthDay News) - Tekturna, a new molecular entity that acts at the earlier stages of the blood pressure regulation process to inhibit hypertension, has been approved by the U.S. Food and Drug Administration.
Tekturna (aliskiren) inhibits renin, a kidney enzyme associated with blood pressure regulation, the agency said in a statement. The drug's effectiveness was demonstrated in six clinical studies involving more than 2,000 people with mild-to-moderate hypertension. Its effects were maintained for up to one year.
As is true for similar drugs, blood pressure reductions among blacks who used Tekturna tended to be lower than for whites and Asians. The drug should not be used by pregnant women, the FDA said.
Common side effects reported during clinical testing included diarrhea, and in rare instances, allergic reactions and difficulty breathing, the agency said.
Tekturna is manufactured by New Jersey-based Novartis Pharmaceuticals Corp.
Copyright 2007 ScoutNews, LLC. All rights reserved.
- Couple urges routine screening for fetal condition
- A Toronto couple whose baby daughter died during childbirth say doctors should make screening for vasa previa a common practice.
- Global tuberculosis epidemic levels off, threats remain: report
- The global tuberculosis epidemic has leveled off, but it could take centuries to eradicate without better drugs and tests for deadly new strains, health officials said Thursday.
- Dental X-rays expose signs of osteoporosis
- Dental X-rays could be used for more than checking on your teeth, as the scans could also help determine if a woman is at risk for osteoporosis, researchers say.
- Cancer society warns of untested drug
- The Canadian Cancer Society is warning people not to self-medicate with the cheap, widely available drug known as DCA.
- Longest-surviving triple-bypass patient dies
- Prince Edward Islander Tommy Hughes, who was recently recognized by Guinness World Records as the longest-surviving triple-bypass patient, died Wednesday in Alberta of lung cancer.